McKesson Closes $2.9B Apollo Deal for Medical-Surgical Unit

McKesson Corporation has closed its previously announced strategic investment with funds managed by Apollo Global Management, selling a minority interest in its Medical-Surgical Solutions business for approximately $2.9 billion in cash. The transaction values the medical supply distribution unit at roughly $8.9 billion in enterprise value — one of the largest healthcare distribution deals in recent memory and a signal that private equity sees durable cash flows in the sector's infrastructure layer.

The deal, first announced in February, gives Apollo a 20% equity stake in the newly formed entity while McKesson retains majority ownership and operational control. It's a structure that's become increasingly common as healthcare operators seek capital partnership without surrendering strategic direction — and as buyout firms look for exposure to resilient, non-cyclical revenue streams that don't require aggressive operational overhauls.

McKesson's Medical-Surgical Solutions distributes consumable medical supplies, equipment, and pharmaceuticals to physician practices, surgical centers, long-term care facilities, and home health providers across the U.S. and Canada. The business generated approximately $7.2 billion in revenue in fiscal 2025, according to company filings, with operating margins in the mid-single digits — consistent with the thin-margin, high-volume economics of wholesale distribution.

Apollo's interest reflects a broader thesis: healthcare supply chains are fragmented, essential, and ripe for consolidation. The fund complex has been methodically building exposure to medical distribution and logistics over the past 18 months, betting that aging demographics and rising procedure volumes will sustain steady demand regardless of reimbursement headwinds or regulatory shifts. This isn't a turnaround play. It's an infrastructure bet dressed up as a minority stake.

From Apollo's side, the investment checks multiple boxes. Medical-surgical distribution sits adjacent to pharmaceuticals but operates with different margin dynamics and fewer pricing controversies. While drug wholesalers face constant scrutiny over PBM relationships and rebate structures, the equipment and consumables side of the business is comparatively quiet — lower profile, lower regulatory risk, and insulated from the pricing theater that dominates Washington's healthcare conversations.

The business also benefits from structural tailwinds. An aging population means more procedures, more chronic disease management, and more demand for everything from gloves and gauze to imaging equipment and diagnostic supplies. Importantly, these aren't purchases that get deferred when the economy wobbles. Surgical centers don't delay orders because interest rates rose. Home health agencies don't skip shipments because tech stocks sold off.

For McKesson, the transaction accomplishes two things at once. First, it unlocks capital — the $2.9 billion proceeds give the company firepower to reinvest in higher-margin segments like oncology networks and pharmacy services, both of which have been strategic priorities for CEO Brian Tyler. Second, it brings in a sophisticated financial partner with deep experience in healthcare services roll-ups, supply chain optimization, and value creation through operational efficiency rather than financial engineering.

McKesson has signaled it intends to use a portion of the proceeds to pay down debt and return capital to shareholders through share repurchases — a move that's already been well-received by equity analysts who've been pushing the company to improve its capital allocation. The company closed fiscal 2025 with net debt of approximately $4.1 billion, and this transaction gives it room to maneuver without sacrificing growth investments.

Medical-surgical distribution is one of those sectors that flies under the radar despite generating billions in revenue. It's not flashy. It doesn't involve breakthrough drugs or cutting-edge devices. It's the invisible infrastructure that keeps healthcare delivery functioning — the supply chain equivalent of water pipes and electrical grids.

The market is dominated by a handful of national players — McKesson, Cardinal Health, Owens & Minor, Henry Schein, and Medline — but remains fragmented at the regional and specialty levels. Thousands of smaller distributors serve niche verticals like dental supplies, veterinary products, or lab equipment, and many of these firms are family-owned, founder-run, and approaching succession events. That's catnip for private equity, which has been quietly assembling roll-up platforms in adjacent verticals.

Customer relationships in this business tend to be sticky. Once a physician practice or surgical center locks in a distributor, switching costs are high — not just financially, but operationally. Reordering systems, inventory management protocols, and staff training all create friction. That stickiness translates into predictable revenue and low customer churn, which in turn supports stable cash flows and modest but reliable margin expansion over time.

What the table doesn't show is margin trajectory. All four companies have been investing in automation, data analytics, and procurement software to eke out incremental efficiency gains. The playbook is consistent: consolidate purchasing, optimize inventory turns, and use scale to negotiate better terms with manufacturers. It's not revolutionary, but it's effective — and it's a model Apollo knows how to accelerate.

This isn't Apollo's first rodeo in healthcare supply chains. The firm has been building a portfolio of distribution, logistics, and services businesses over the past several years, including investments in pharmacy benefit managers, specialty pharmacy platforms, and healthcare IT infrastructure. The McKesson deal fits squarely within that broader strategy: buying into established, cash-generative businesses that sit at critical junctures in healthcare delivery.

The structure of the transaction is worth unpacking. Apollo isn't buying control. McKesson retains majority ownership and operational authority, which means the business continues to operate under the McKesson brand with the existing management team in place. But Apollo's 20% stake comes with Board representation, governance rights, and a seat at the table for strategic decisions — particularly around M&A, capital allocation, and growth investments.

That setup gives Apollo influence without the headaches of day-to-day operations. It's a model the firm has used before in sectors where scale and operational complexity make full buyouts less attractive. By taking a minority position with governance protections, Apollo can shape strategy, push for value-creation initiatives, and position itself for an eventual exit — either through an IPO, a sale to a strategic buyer, or a continuation fund structure.

For McKesson, the governance arrangement provides discipline. Having a sophisticated financial partner scrutinizing capital deployment and strategic choices can force tougher conversations and sharper prioritization. It's a built-in accountability mechanism — one that's especially valuable in a business where incremental improvement matters more than moonshot innovation.

The new entity will operate as a standalone business unit with its own financial reporting, though it remains consolidated within McKesson's overall results. That separation creates optionality down the line — if market conditions are favorable, the business could be spun out or taken public independently. If not, it continues as a captive unit with external capital support.

One detail that didn't make the press release: Apollo's stake includes liquidation preferences and tag-along rights, according to the transaction documents filed with the SEC. That means if McKesson decides to sell the business outright, Apollo gets paid out first up to a certain threshold, and it can force its shares to be included in any sale. Those aren't unusual provisions in minority investment structures, but they do tilt the power balance slightly toward the financial partner in exit scenarios.

The implied enterprise value of $8.9 billion puts the business at roughly 1.2x revenue and approximately 20-22x trailing EBITDA, based on McKesson's disclosed segment financials. That multiple isn't cheap by distribution standards, but it's not outrageous either — particularly for a business with national scale, diversified end markets, and modest but stable margin expansion.

For context, recent comparable transactions in healthcare distribution have traded in the 18-25x EBITDA range depending on growth profile and margin trajectory. Medline's 2021 LBO by Blackstone, Carlyle, and Hellman & Friedman reportedly valued that business at north of 20x EBITDA, while Owens & Minor's acquisition of Apria Healthcare in 2022 came in closer to 18x. Apollo's valuation here suggests confidence in the business's growth trajectory and margin improvement potential.

This deal is part of a deliberate portfolio rebalancing by McKesson, which has been shifting capital away from lower-margin distribution and toward higher-margin specialty services. Over the past three years, the company has exited businesses in Europe, sold its stake in Change Healthcare, and doubled down on oncology practice management through its U.S. Oncology Network.

The Medical-Surgical Solutions unit was a logical candidate for partial monetization. It's a good business — stable, profitable, strategically important — but it doesn't align with McKesson's highest-return opportunities. Oncology services, specialty pharmacy, and biopharma commercialization all offer significantly higher margins and faster growth. By keeping majority ownership but bringing in a financial partner, McKesson gets the best of both worlds: liquidity today and upside participation tomorrow.

CEO Brian Tyler framed the transaction as "unlocking value while maintaining strategic control" in the original announcement. That's corporate-speak, but it's not wrong. The business remains core to McKesson's integrated distribution model — particularly its relationships with physician practices and ambulatory care facilities — but it no longer needs to be 100% owned to deliver strategic value.

Investors have mostly applauded the move. McKesson's stock is up roughly 8% since the deal was first announced in February, outpacing the broader healthcare distribution sector. Analysts at Jefferies, Baird, and Evercore ISI have all maintained Buy ratings, citing improved capital allocation and reduced leverage as key positives.

McKesson has been explicit about its capital deployment priorities. The company plans to use the $2.9 billion in proceeds for debt reduction, share repurchases, and strategic investments in higher-growth segments. Management disclosed on its most recent earnings call that it expects to retire approximately $1.5 billion in near-term maturities, buy back $800 million in stock over the next 12 months, and retain the remainder for opportunistic M&A.

The debt paydown is straightforward — it lowers interest expense, improves leverage ratios, and gives the company more flexibility if capital markets tighten. The share repurchases signal confidence in the stock's valuation and return excess cash to shareholders in a tax-efficient manner. The M&A reserve is where things get interesting.

Now that the transaction has closed, the operational work begins. McKesson and Apollo must establish governance protocols, align on strategic priorities, and integrate Apollo's operational resources into the business. That includes defining decision rights, setting performance targets, and identifying value-creation initiatives that both parties agree on.

One near-term priority, according to sources familiar with the matter, is accelerating the business's digital transformation. Medical-surgical distribution has historically been a phone-and-fax operation, but the industry is slowly moving toward e-commerce platforms, automated reordering systems, and data-driven inventory management. Apollo has portfolio companies with expertise in those areas, and there's an expectation that the firm will bring operational playbooks from other investments to bear here.

Those figures are preliminary and based on industry benchmarks, not specific McKesson guidance. But they give a sense of where Apollo is likely to push. The firm didn't invest $2.9 billion to sit on its hands. Expect near-term capex to rise as the business modernizes, with the payoff coming in the form of lower operating costs and improved service levels over the next three to five years.

Regulatory approvals were never a major hurdle here. The transaction didn't trigger antitrust concerns because Apollo isn't a direct competitor in healthcare distribution, and the deal doesn't meaningfully change market concentration. The Federal Trade Commission reviewed the transaction under standard Hart-Scott-Rodino procedures and cleared it without conditions in April.

The McKesson-Apollo deal is a data point in a broader trend: healthcare distribution is attracting institutional capital at a scale and pace that didn't exist five years ago. Private equity has always been active in healthcare services, but distribution was long seen as too capital-intensive, too low-margin, and too operationally complex to generate venture-style returns.

That calculus has shifted. With interest rates normalizing and growth harder to come by in traditional buyout sectors like software and consumer, firms like Apollo are revisiting businesses with durable cash flows, inflation pass-through mechanisms, and structural demand drivers. Healthcare distribution checks all three boxes.

There's also a defensive element to the thesis. As healthcare delivery shifts away from hospitals and toward ambulatory settings, the companies that control supply chains to physician practices, surgical centers, and home health agencies gain strategic importance. That's not a trend that reverses if the economy slows or if reimbursement rates get squeezed. If anything, it accelerates — lower-cost settings become more attractive when payers tighten budgets.

Apollo's bet is that this business, with the right capital support and operational improvements, can sustain mid-single-digit revenue growth and gradually expand margins by 50-100 basis points over the next five years. That's not explosive, but it's compounding — and in a world where reliable compounding is scarce, it's enough to justify a $2.9 billion check.

No deal is without risks, and this one has a few lurking beneath the surface. First, reimbursement pressure is real. While medical-surgical distribution isn't directly tied to Medicare rates, the end customers — physician practices, surgical centers, nursing homes — are. If reimbursement cuts force those customers to consolidate or close, demand falls.

Second, the business faces margin compression from large group purchasing organizations (GPOs) and integrated delivery networks that increasingly bypass distributors and negotiate directly with manufacturers. McKesson has mitigated that risk by building value-added services around the core distribution offering, but the threat hasn't disappeared.

Third, there's execution risk in the digital transformation Apollo is likely to push. Modernizing legacy warehouse management systems, integrating e-commerce platforms, and training frontline staff on new tools is expensive, disruptive, and prone to delays. If the technology investments don't deliver the promised ROI, the margin expansion story falls apart.

Finally, there's the governance dynamic. McKesson retains operational control, but Apollo has Board seats and veto rights on major decisions. That creates potential for friction if the two parties disagree on strategy, particularly around M&A or capital allocation. Minority investments with strong governance provisions can be messy when interests diverge.